# The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II

> **NCT02281838** · PHASE2 · TERMINATED · sponsor: **University of Alberta** · enrollment: 142 (actual)

## Conditions studied

- Intracerebral Hemorrhage

## Interventions

- **DRUG:** labetalol/hydralazine/enalapril

## Key facts

- **NCT ID:** NCT02281838
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08-01
- **Primary completion:** 2021-11
- **Final completion:** 2021-12
- **Target enrollment:** 142 (ACTUAL)
- **Why stopped:** Slow enrolment after publication of the Interact III study
- **Last updated:** 2024-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02281838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02281838, "The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02281838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*